Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
Second-Line Liposomal Irinotecan Added to NCCN Guideline for Pancreatic Cancer
March 24th 2016The combination of liposomal irinotecan (irinotecan liposome injection; Onivyde), fluorouracil, and leucovorin has been added to the 2016 NCCN Clinical Practice Guidelines in Oncology as a second-line treatment for patients with gemcitabine-refractory metastatic pancreatic cancer.
Read More
CAR T-cells Rapidly Evolving as Cancer Therapies
March 20th 2016Chimeric antigen receptor-modified T-cell therapies have demonstrated durable complete responses for patients with relapsed/refractory B-cell acute lymphoblastic leukemia; however, several questions remain regarding their optimal use and applicability outside of this disease.
Read More
Extended Phase III Data Illuminates Ibrutinib Survival Benefit in CLL
March 20th 2016Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.
Read More
Potential of Immuno-Oncology Continues to Expand
March 19th 2016Immuno-oncology has advanced rapidly, with the introduction of immune checkpoint inhibition and effective adoptive T-cell therapies. As these agents rush through development, several questions remain regarding the optimal patients for treatment and the next steps for further improving outcomes.
Read More
Frontline Ibrutinib Highly Effective Across Subgroups for Elderly Patients With CLL/SLL
March 18th 2016Frontline treatment with ibrutinib reduced the risk of progression or death by 84% compared with single-agent chlorambucil for elderly patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
Earlier Abiraterone More Effective for Chemo-Naïve mCRPC
March 14th 2016Treatment with abiraterone acetate plus prednisone demonstrated an 11.8-month improvement in overall survival compared with prednisone and placebo for men with less advanced, chemotherapy-naïve metastatic castration-resistant prostate cancer.
Read More
Alpelisib Combo Promising in PIK3CA-Altered, Heavily Pretreated Breast Cancer
March 12th 2016The combination of the alpha-specific PI3K inhibitor alpelisib (BYL719) and fulvestrant (Faslodex) demonstrated promising early efficacy and mild toxicity in heavily pretreated postmenopausal women with ER-positive metastatic breast cancer.
Read More
CAR T-cell Therapies Effective Across Hematologic Malignancies
March 2nd 2016Chimeric antigen receptor-modified T-cell therapies continue to demonstrate promising signs of efficacy for patients with hematologic malignancies, including those with acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Read More
Durvalumab Granted Breakthrough Status for Bladder Cancer
February 17th 2016The FDA has granted a breakthrough therapy designation to durvalumab as a treatment for patients with PD-L1–positive inoperable or metastatic urothelial bladder cancer following progression on prior treatment with a platinum-based regimen.
Read More
Neratinib Improves DFS in HER2-Positive Breast Cancer
February 12th 2016Treatment with the tyrosine kinase inhibitor neratinib demonstrated a 2-year disease-free survival rate of 93.9% in patients with early-stage HER2-positive breast cancer, representing a 33% improvement compared with placebo.
Read More
Patient Populations Provide Sequencing Clues in Chemorefractory CRC
February 11th 2016Treating patients with chemorefractory advanced colorectal cancer has undergone a significant transformation in recent years. Now, with two agents approved, the optimal sequence for therapies regorafenib and TAS-102 becomes the next relevant question.
Read More
Osimertinib Approved in Europe for EGFR T790M-Mutant NSCLC
February 3rd 2016The European Commission has granted a conditional marketing authorization to osimertinib for patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer, regardless of prior treatment with EGFR TKI.
Read More
Second-Line Cabozantinib Shows Rare Survival Advantage in RCC
February 1st 2016The second interim analysis of the phase III METEOR trial has revealed a statistically significant improvement in overall survival with cabozantinib (Cometriq) versus everolimus as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.
Read More
Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD
January 29th 2016Treatment with allogeneic anti–CD19 chimeric antigen receptor–modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.
Read More